Merck & Co Inc
NYSE: MRK
$96.62
-$1.74 (-1.8%)
Real Time Data Delayed 15 Min.
MRK Articles
thinkstockApril 14, 2015: Markets opened higher on again on Tuesday but all three major indexes slipped below the breakeven line soon thereafter. The S&P 500 and the DJIA pulled back into...
Published:
Last Updated:
The 30-year Treasury Bond yields only about 2.5% and, amazingly, more than half of the 30 Dow Jones Industrial Average stocks are yielding more than that.
Published:
SunTrust Robinson Humphrey analysts expect the pharmaceutical industry to outperform in 2015, driven in part by a solid new product cycle and an attractive five-year growth rate.
Published:
thinkstockMarch 18, 2015: Markets opened lower on Wednesday and bided its time below the break-even line until just after 2 p.m. and the FOMC’s announcement that it would no longer wait patiently...
Published:
Last Updated:
A new research report from SunTrust Robinson Humphrey is very positive on pharmaceuticals, and the analysts expect the sector to outperform this year.
Published:
With AT&T dropped from the Dow in favor of Apple, investors may be wondering which Dow stocks could get booted from the index next.
Published:
thinkstock February 9, 2015: Markets opened lower on Monday following remarks by Greece’s new president that rattled traders. There was no U.S. economic data out today. Shortly before the closing...
Published:
Last Updated:
If there is one thing that the pharmaceutical industry tries to shy away from it is the controversy over the costs of some of the drugs on the market today.
Published:
Merck reported largely in-line fourth-quarter financial results Wednesday before the U.S. markets opened.
Published:
24/7 Wall St. has put together a preview of some of the larger companies reporting quarterly results in the coming week.
Published:
Merck shares posted a new 52-week high last Tuesday and closed Friday less than a buck from that high. Year to date, Its shares are up 11%.
Published:
Last Updated:
One key consideration for the year ahead is that the Pfizer of 2016 or 2017 is likely to be night and day different from the Pfizer of 2005.
Published:
One key consideration for the year ahead is Merck's acquisitions of Idenix and Cubist Pharmaceuticals to expand its product offerings
Published:
Last Updated:
One key consideration for the year ahead is that Johnson & Johnson raised its dividends again and managed to have upside performance above what was expected.
Published:
thinkstockJanuary 7, 2015: Markets opened higher on Wednesday after ADP and TrimTab reports on unemployment came in a shade above expectations. The U.S. trade balance improved in November primarily...
Published:
Last Updated: